Latigo Biotherapeutics
- Market cap
- 1.03B
- P/E (TTM)i
- -9.26
- P/Bi
- -3.73
- EPSi
- -1.82
- Div yieldi
- 0.00%
- 52W posi
- 2%
Anonymous reader poll. Unscientific, not investment advice.
Shares of Latigo Biotherapeutics closed at 15.52, down 4.55%. That leaves the company valued at approximately 1.03B, the #3230 most valuable US-listed company we track. Across 3 analysts the consensus rating is Buy, with an average price target of 57.67 (+272%). Against a 52-week band of 15.27-25.93, the shares are currently 2% of the way up.
✦ StockVane Quant Insights how this is computed
- Not yet in the StockVane Momentum strategy's universe - this name needs price history back to 2021 for a reliable signal and doesn't have it yet (most often because it IPO'd or was spun off more recently). This grade is a preliminary blend of valuation, momentum and analyst data, not a Momentum buy/sell call.
- Valuation sits at the 91% percentile of its own 5-year range.
- Analyst consensus across 3 analysts is Buy.
- Main-fund capital flow has been a net outflow over the last 43 sessions.
- Short interest has risen to 0.7% of float.
- Analyst tilt is Buy.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Key statistics
Price & volume
- Prev close
- 16.26
- Open
- 16.22
- Day range
- 15.27 - 16.35
- Avg price
- 15.57
- Volume
- 241.51K
- Turnover
- 3.76M
- Turnover ratei
- 1.51%
- Volume ratioi
- 0.51
- Amplitudei
- 6.62%
- 52-week rangei
- 15.27 - 25.93
Valuation
- P/Ei
- -8.55
- P/E (TTM)i
- -9.26
- P/Bi
- -3.73
- EPSi
- -1.82
- Book value / shi
- -4.16
- Net profit
- -120.33M
- Net assets
- -276.07M
Share structure
- Market cap
- 1.03B
- Float capi
- 248.32M
- Shares out
- 66.30M
- Float sharesi
- 16.00M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2026-08-07
40.1% below the 52-week high
Trading activity
Net capital flow main funds, last 43 sessions
-5.62M net over the window
Short interest
- Shares short
- 449.96K
- % of floati
- 0.68%
- Days to coveri
- 2.11
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Latigo Biotherapeutics (LTGO)?
Latigo Biotherapeutics last traded at 15.52. The quote on this page refreshes every few seconds while US markets are open.
What is Latigo Biotherapeutics's market cap?
About 1.03B.
What is the P/E ratio of Latigo Biotherapeutics?
The trailing twelve-month P/E is -9.26. The Valuation tab shows it against the stock's own five-year range.
Does Latigo Biotherapeutics pay a dividend?
Latigo Biotherapeutics does not currently pay a regular dividend.
Is Latigo Biotherapeutics a buy according to analysts?
The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 57.67, which implies 271.6% upside from the current price. This is not investment advice.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.